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Please note: 
Within this document you find general information about the drug of interest and the indication it is 
intended to be used for. Further we have included full text publications of phase III trials, assessing 
the safety and efficacy of the drugs of interest. 
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Introduction 
As part of the project „Horizon Scanning in Oncology“ (further information can be found here: 
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie), 9 information sources are scanned 
frequently to identify emerging anticancer drugs. 
Every 3 months, these anticancer therapies are filtered (i.e. in most cases defined as availability of 
phase III results; for orphan drugs also phase II) to identify drugs at/around the same time as the 
accompanying drug licensing decisions of the EMA.  
An expert panel consisting of oncologists and pharmacists then applies 5 prioritisation criteria to elicit 
those anti-cancer therapies which might be associated with either a considerable impact on financial 
resources or a substantial health benefit.  
For the 41st prioritisation (10/2019), ten drugs were filtered out of 578 identified and were sent to 
prioritisation. Of these, three drugs were ranked as ‘highly relevant’ by the expert panel, seven as 
‘relevant’ and none as ‘not relevant’. For ‘highly relevant’ drugs, further information including, for 
example, abstracts of phase III studies and licensing status is contained in this document. 
The summary judgements of the expert panel for all prioritised drugs are provided in the following 
table. 
 
No. Filtered Drugs – 41st prioritisation 4th quarter 2019 Overall category 
1. 
Atezolizumab (Tecentriq®) plus bevacizumab versus sunitinib in 
patients with previously untreated metastatic renal cell carcinoma 
(RCC) 
Relevant 
2. 
Atezolizumab (Tecentriq®) in combination with carboplatin plus 
nab-paclitaxel chemotherapy compared with chemotherapy alone 
as first-line treatment for metastatic non-squamous NSCLC 
Highly relevant 
3. Nivolumab (Opdivo®) plus ipilimumab in advanced NSCLC Highly relevant 
4. Encorafenib, binimetinib (Mektovi®), and cetuximab in BRAF V600E–mutated colorectal cancer (CRC) Relevant 
5. Cabazitaxel (Jevtana®) versus abiraterone or enzalutamide in 
metastatic prostate cancer Relevant 
6. 
Androgen deprivation therapy (ADT) with enzalutamide (Xtandi®) 
or placebo in men with metastatic hormone-sensitive prostate 
cancer (HSPC) 
Highly relevant 
7. Niraparib (Zejula®) in patients with newly diagnosed advanced 
ovarian cancer Relevant 
8. Veliparib (ABT-888) with first-line chemotherapy and as 
maintenance therapy in ovarian cancer Relevant 
9. Pexidartinib (TuralioTM) versus placebo for advanced tenosynovial giant cell tumour (TGCT) Relevant 
10. Quizartinib (AC220) versus salvage chemotherapy in relapsed or 
refractory FLT3-ITD acute myeloid leukaemia (AML) Relevant 
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Lung cancer 
Atezolizumab (Tecentriq®) in combination with carboplatin plus 
nab-paclitaxel chemotherapy compared with chemotherapy alone 
as first-line treatment for metastatic non-squamous non-small cell 
lung cancer (NSCLC) 
Overview 
Drug Description atezolizumab is a humanised IgG1 anti- programmed death-ligand 1 (PD-L1) monoclonal antibody 
Patient Indication 
patients with histologically or cytologically confirmed stage IV non-
squamous NSCLC who received no previous chemotherapy (for stage IV 
non-squamous NSCLC) 
Incidence in 
Austria 
cancer of the lung, trachea and bronchia: 4,877 newly diagnosed per year 
(2016), 57.3/100,000/year (European Standard Population, 2013) [1]. 
NSCLC is the most common type of lung cancer (85-90% of lung cancer 
cases). 
Current standard 
treatment 
a for locally advanced or metastatic NSCLC, the aim of treatment is 
to prolong survival, improve quality of life, and control disease-
related symptoms 
a treatment strategies should take into account the tumour histology 
and molecular pathology, as well as the patient’s age, performance 
status, comorbidities, and preferences 
a patients who smoke should be encouraged to cease, as cessation 
improves treatment outcomes 
a the following are recommended for first-line treatment of patients 
with advanced non-squamous (stages IIIB and IV) NSCLC, and no 
specific modifications to the epidermal growth factor receptor 
(EGFR) or ALK genes:  
- PD-L1 under 50% (no gene mutation, fusion protein or 
biomarker): 
o atezolizumab plus bevacizumab, carboplatin and 
paclitaxel 
o pembrolizumab, with pemetrexed and platinum 
chemotherapy 
o pemetrexed in combination with cisplatin 
- PD-L1 50% or over (no gene mutation, fusion protein or 
biomarker): 
o pembrolizumab, with pemetrexed and platinum 
chemotherapy 
o pembrolizumab [2, 3]. 
Ongoing Phase III 
NCT02367781 (IMpower130) until 12/2019 
NCT03991403 until 12/2022 
NCT02366143 until 12/2019 
NCT02657434 until 11/2019 
NCT02409342 until 04/2022 [4] 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
according to product information (03/2019), atezolizumab is indicated: 
a as monotherapy for the treatment of adult patients with locally 
advanced or metastatic urothelial carcinoma (UC): 
- after prior platinum-containing chemotherapy, or  
- who are considered cisplatin ineligible, and whose tumours 
have a PD-L1 expression ≥ 5%  
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a in combination with bevacizumab, paclitaxel and carboplatin for the 
first-line treatment of adult patients with metastatic non-squamous 
NSCLC. In patients with EGFR mutant or ALK-positive NSCLC, 
atezolizumab, in combination with bevacizumab, paclitaxel and 
carboplatin, is indicated only after failure of appropriate targeted 
therapies 
a as monotherapy is indicated for the treatment of adult patients with 
locally advanced or metastatic NSCLC after prior chemotherapy. 
Patients with EGFR mutant or ALK-positive NSCLC should also 
have received targeted therapies before receiving atezolizumab 
[5]. 
FDA 
according to label information (03/2019), atezolizumab is indicated in: 
a UC: 
- for the treatment of adult patients with locally advanced or 
metastatic UC who:  
o are not eligible for cisplatin-containing 
chemotherapy and whose tumors express PD-L1 
(PD-L1 stained tumor-infiltrating immune cells  
covering ≥ 5% of the tumor area), as determined by 
an FDA-approved test, or  
o are not eligible for any platinum-containing 
chemotherapy regardless of PD-L1 status, or  
o have disease progression during or following any 
platinum-containing chemotherapy, or within 12 
months of neoadjuvant or adjuvant chemotherapy 
(accelerated approval)  
a NSCLC: 
- in combination with bevacizumab, paclitaxel, and 
carboplatin, for the first-line treatment of adult patients with 
metastatic non-squamous NSCLC with no EGFR or ALK 
genomic tumor aberrations 
- for the treatment of adult patients with metastatic NSCLC 
who have disease progression during or following platinum-
containing chemotherapy. Patients with EGFR or ALK 
genomic tumor aberrations should have disease 
progression on FDA-approved therapy for NSCLC 
harboring these aberrations prior to receiving atezolizumab 
a Triple-Negative Breast Cancer (TNBC):  
- in combination with paclitaxel protein-bound for the 
treatment of adult patients with unresectable locally 
advanced or metastatic TNBC whose tumors express PD-
L1 (PD-L1 stained tumor-infiltrating IC of any intensity 
covering ≥ 1% of the tumor area), as determined by an FDA 
approved test (accelerated approval)  
a Small Cell Lung Cancer (SCLC): 
- in combination with carboplatin and etoposide, for the first-
line treatment of adult patients with extensive-stage small 
cell lung cancer (ES-SCLC) [6].  
Costs  
Tecentriq® 1200 mg concentrate for solution for infusion = € 4,799.20 (ex-
factory price) [7] 
 
IMpower130 trial patients received induction atezolizumab treatment (1200 
mg intravenously every 3 weeks) in combination with chemotherapy 
comprising carboplatin plus nab-paclitaxel or chemotherapy alone 
according to the same schedule for four or six 21-day cycles. The number 
of induction treatment cycles (four or six) was at the discretion of the 
investigator and determined or documented before randomisation. 
Following induction, patients in the atezolizumab plus chemotherapy group 
received maintenance treatment with 1200 mg intravenous atezolizumab 
and patients in the chemotherapy group received best supportive care or 
pemetrexed switch maintenance therapy, at the investigator’s discretion. In 
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the atezolizumab plus chemotherapy group, maintenance therapy was 
administered until investigator-assessed loss of clinical benefit or toxicity. 
 
Induction treatment: 1 cycle = € 4,799.20, 4 cycles € 19,196.8,  
6 cycles € 28,795.2 -> + costs for  chemotherapy 
Maintenance phase: 1200 mg atezolizumab/every 3 weeks = € 
4,799.20/one dose. Mean treatment duration in the atezolizumab plus 
chemotherapy group was 8.9 months for atezolizumab -> approx. 12 doses 
= € 57,590.4 
1.1.1 Published articles (PubMed): 
Lancet Oncology; available online May 20, 2019 (West et al.): “Atezolizumab in combination with 
carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line 
treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, 
randomised, open-label, phase 3 trial” [8]  
 
Background  
Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved 
overall survival in patients with previously treated non-small-cell lung cancer and also showed clinical 
benefit when combined with chemotherapy as first-line treatment of non-small-cell lung cancer. 
IMpower130 aimed to assess the efficacy and safety of atezolizumab plus chemotherapy versus 
chemotherapy alone as first-line therapy for non-squamous non-small-cell lung cancer. 
 
Methods  
IMpower130 was a multicentre, randomised, open-label, phase 3 study done in 131 centres across 
eight countries (the USA, Canada, Belgium, France, Germany, Italy, Spain, and Israel). Eligible 
patients were aged 18 years or older, and had histologically or cytologically confirmed stage IV non-
squamous non-small-cell lung cancer, an Eastern Cooperative Oncology Group performance status 
of 0 or 1, and received no previous chemotherapy for stage IV disease. Patients were randomly 
assigned (2:1; permuted block [block size of six] with an interactive voice or web response system) 
to receive atezolizumab (1200 mg intravenously every 3 weeks) plus chemotherapy (carboplatin 
[area under the curve 6 mg/mL per min every 3 weeks] plus nab-paclitaxel [100 mg/m² intravenously 
every week]) or chemotherapy alone for four or six 21-day cycles followed by maintenance therapy. 
Stratification factors were sex, baseline liver metastases, and PD-L1 tumour expression. Co-primary 
endpoints were investigator-assessed progression-free survival and overall survival in the intention-
to-treat wild-type (ie, EGFRwt and ALKwt) population. The safety population included patients who 
received at least one dose of the study drug. This study is registered with ClinicalTrials.gov, number 
NCT02367781. 
 
Findings  
Between April 16, 2015, and Feb 13, 2017, 724 patients were randomly assigned and 723 were 
included in the intention-to-treat population (one patient died before randomisation, but was assigned 
to a treatment group; this patient was excluded from the intention-to-treat population) of the 
atezolizumab plus chemotherapy group (483 patients in the intention-to-treat population and 451 
patients in the intention-to-treat wild-type population) or the chemotherapy group (240 patients in the 
intention-to-treat population and 228 patients in the intention-to-treat wild-type population). Median 
follow-up in the intention-to-treat wild-type population was similar between groups (18.5 months [IQR 
15.2–23.6] in the atezolizumab plus chemotherapy group and 19·2 months [15.4–23.0] in the 
chemotherapy group). In the intention-to-treat wild-type population, there were significant 
improvements in median overall survival (18.6 months [95% CI 16.0–21.2] in the atezolizumab plus 
chemotherapy group and 13.9 months [12.0–18.7] in the chemotherapy group; stratified hazard ratio 
[HR] 0.79 [95% CI 0.64–0.98]; p=0.033) and median progression-free survival (7.0 months [95% CI 
6.2–7.3] in the atezolizumab plus chemotherapy group and 5.5 months [4.4–5.9] in the chemotherapy 
group; stratified HR 0.64 [95% CI 0.54–0.77]; p<0.0001]). The most common grade 3 or worse 
treatment-related adverse events were neutropenia (152 [32%] of 473 in the atezolizumab plus 
chemotherapy group vs. 65 [28%] of 232 in the chemotherapy group), anaemia (138 [29%] vs. 47 
[20%]), and decreased neutrophil count (57 [12%] vs. 19 [8%]). Treatment-related serious adverse 
events were reported in 112 (24%) of 473 patients in the atezolizumab plus chemotherapy group and 
30 (13%) of 232 patients in the chemotherapy group. Treatment-related (any treatment) deaths 
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occurred in eight (2%) of 473 patients in the atezolizumab plus chemotherapy group and one (<1%) 
of 232 patients in the chemotherapy group. 
 
Interpretation  
IMpower130 showed a significant and clinically meaningful improvement in overall survival and a 
significant improvement in progression-free survival with atezolizumab plus chemotherapy versus 
chemotherapy as first-line treatment of patients with stage IV non-squamous non-small-cell lung 
cancer and no ALK or EGFR mutations. No new safety signals were identified. This study supports 
the benefit of atezolizumab, in combination with platinum-based chemotherapy, as first-line treatment 
of metastatic non-small-cell lung cancer. 
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Nivolumab (Opdivo®) plus ipilimumab in advanced NSCLC 
Overview 
Drug Description nivolumab is a a fully human anti–PD-1 antibody 
Patient Indication patients with squamous or non-squamous stage IV or recurrent NSCLC 
Incidence in 
Austria 
cancer of the lung, trachea and bronchia: 4,877 newly diagnosed per year 
(2016), 57.3/100,000/year (European Standard Population, 2013) [1]. 
NSCLC is the most common type of lung cancer (85-90% of lung cancer 
cases). 
Current standard 
treatment 
a for locally advanced or metastatic NSCLC, the aim of treatment is 
to prolong survival, improve quality of life, and control disease-
related symptoms 
a treatment strategies should take into account the tumour histology 
and molecular pathology, as well as the patient’s age, performance 
status, comorbidities, and preferences 
a patients who smoke should be encouraged to cease, as cessation 
improves treatment outcomes 
a the following are recommended for first-line treatment of patients 
with advanced non-squamous (stages IIIB and IV) NSCLC, and no 
specific modifications to the EGFR or ALK genes:  
- PD-L1 under 50% (no gene mutation, fusion protein or 
biomarker): 
o Atezolizumab plus bevacizumab, carboplatin and 
paclitaxel 
o pembrolizumab, with pemetrexed and platinum 
chemotherapy 
o pemetrexed in combination with cisplatin 
- PD-L1 50% or over (no gene mutation, fusion protein or 
biomarker): 
o pembrolizumab, with pemetrexed and platinum 
chemotherapy 
o pembrolizumab [2, 3]. 
Ongoing Phase III 
NCT02477826 (CheckMate 227) until 08/2022 
NCT03469960 until 05/2023 
NCT03351361 until 06/2022 
NCT03215706 until 11/2020 [4] 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
according to product information (10/2019), nivolumab is indicated in: 
a melanoma: 
o as monotherapy or in combination with ipilimumab for the 
treatment of advanced (unresectable or metastatic) 
melanoma in adults. Relative to nivolumab monotherapy, 
an increase in progression-free survival (PFS) and overall 
survival (OS) for the combination of nivolumab with 
ipilimumab is established only in patients with low tumour 
PD-L1 expression. 
a adjuvant treatment of melanoma: 
o as monotherapy for the adjuvant treatment of adults with 
melanoma with involvement of lymph nodes or metastatic 
disease who have undergone complete resection 
a NSCLC:  
o as monotherapy for the treatment of locally advanced or 
metastatic NSCLC after prior chemotherapy in adults.  
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a renal cell carcinoma (RCC): 
o as monotherapy is for the treatment of advanced RCC after 
prior therapy in adults 
o nivolumab in combination with ipilimumab is indicated for 
the first-line treatment of adult patients with 
intermediate/poor-risk advanced RCC  
a classical Hodgkin Lymphoma (cHL):  
o as monotherapy for the treatment of adult patients with 
relapsed or refractory cHL after autologous stem cell 
transplant (ASCT) and treatment with brentuximab vedotin 
a squamous cell cancer of the head and neck (SCCHN): 
o as monotherapy is for the treatment of recurrent or 
metastatic SCCHN in adults progressing on or after 
platinum-based therapy 
a UC:  
o as monotherapy is for the treatment of locally advanced 
unresectable or metastatic UC in adults after failure of prior 
platinum-containing therapy [5]. 
FDA 
according to label information (09/2019) nivolumab is indicated for the 
treatment of: 
a patients with unresectable or metastatic melanoma, as a single 
agent or in combination with ipilimumab 
a patients with melanoma with lymph node involvement or metastatic 
disease who have undergone complete resection, in the adjuvant 
setting 
a patients with metastatic NSCLC and progression on or after 
platinum-based chemotherapy. Patients with EGFR or ALK 
genomic tumor aberrations should have disease progression on 
FDA-approved therapy for these aberrations prior to receiving 
nivolumab 
a patients with metastatic SCLC with progression after platinum-
based chemotherapy and at least one other line of therapy 
a patients with advanced RCC who have received prior anti-
angiogenic therapy 
a patients with intermediate or poor risk, previously untreated 
advanced RCC, in combination with ipilimumab 
a adult patients with cHL that has relapsed or progressed after: 
o autologous hematopoietic stem cell transplantation (HSCT) 
and brentuximab vedotin, or  
o 3 or more lines of systemic therapy that includes 
autologous HSCT 
a patients with recurrent or metastatic SCCHN with disease 
progression on or after a platinum-based therapy 
a patients with locally advanced or metastatic UC who:  
o have disease progression during or following platinum-
containing chemotherapy  
o have disease progression within 12 months of neoadjuvant 
or adjuvant treatment with platinum-containing 
chemotherapy 
a adult and paediatric (12 years and older) patients with microsatellite 
instability-high (MSI-H) or mismatch repair deficient (dMMR) 
metastatic CRC that has progressed following treatment with a 
fluoropyrimidine, oxaliplatin, and irinotecan, as a single agent or in 
combination with ipilimumab 
a patients with hepatocellular carcinoma who have been previously 
treated with sorafenib [6]. 
Costs  
4 ml Opdivo® concentrate for solution for infusion 10 mg/ml  = € 572.00 (ex-
factory price) 
10 ml Opdivo® concentrate for solution for infusion 10 mg/ml = € 1430.00 
(ex-factory price) [7] 
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CheckMate 227 trial patients in Part 1a  were randomly assigned in a 1:1:1 
ratio to receive nivolumab (at a dose of 3 mg per kilogram of body weight 
every 2 weeks) plus ipilimumab, nivolumab monotherapy (240 mg every 2 
weeks), or platinum-doublet chemotherapy every 3 weeks for up to four 
cycles.  
In Part 1b, patients were randomly assigned in a 1:1:1 ratio to receive 
nivolumab plus ipilimumab, nivolumab (360 mg every 3 weeks) plus 
platinum-doublet chemotherapy (every 3 weeks for up to four cycles), or 
platinum-doublet chemotherapy alone (every 3 weeks for up to four cycles). 
 
Assuming an average body weight of 70 kg, 210 mg of nivolumab would be 
needed for one dose = € 3,432.00 
 
1.1.2 Published articles (PubMed): 
NEJM; available online September 28, 2019 (Hellmann et al.): “Nivolumab plus Ipilimumab in 
Advanced Non–Small-Cell Lung Cancer” [9] 
 
Background  
In an early-phase study involving patients with advanced non–small-cell lung cancer (NSCLC), the 
response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, 
particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data 
are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC. 
 
Methods  
In this open-label, phase 3 trial, we randomly assigned patients with stage IV or recurrent NSCLC 
and a PD-L1 expression level of 1% or more in a 1:1:1 ratio to receive nivolumab plus ipilimumab, 
nivolumab alone, or chemotherapy. The patients who had a PD-L1 expression level of less than 1% 
were randomly assigned in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab plus 
chemotherapy, or chemotherapy alone. All the patients had received no previous chemotherapy. The 
primary end point reported here was overall survival with nivolumab plus ipilimumab as compared 
with chemotherapy in patients with a PD-L1 expression level of 1% or more. 
 
Findings  
Among the patients with a PD-L1 expression level of 1% or more, the median duration of overall 
survival was 17.1 months (95% confidence interval [CI], 15.0 to 20.1) with nivolumab plus ipilimumab 
and 14.9 months (95% CI, 12.7 to 16.7) with chemotherapy (P = 0.007), with 2-year overall survival 
rates of 40.0% and 32.8%, respectively. The median duration of response was 23.2 months with 
nivolumab plus ipilimumab and 6.2 months with chemotherapy. The overall survival benefit was also 
observed in patients with a PD-L1 expression level of less than 1%, with a median duration of 17.2 
months (95% CI, 12.8 to 22.0) with nivolumab plus ipilimumab and 12.2 months (95% CI, 9.2 to 14.3) 
with chemotherapy. Among all the patients in the trial, the median duration of overall survival was 
17.1 months (95% CI, 15.2 to 19.9) with nivolumab plus ipilimumab and 13.9 months (95% CI, 12.2 
to 15.1) with chemotherapy. The percentage of patients with grade 3 or 4 treatment-related adverse 
events in the overall population was 32.8% with nivolumab plus ipilimumab and 36.0% with 
chemotherapy. 
 
Interpretation  
First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival 
than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level. No new 
safety concerns emerged with longer follow-up. (Funded by Bristol-Myers Squibb and Ono 
Pharmaceutical; CheckMate 227 ClinicalTrials.gov number, NCT02477826.)  
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Prostate cancer 
Androgen deprivation therapy (ADT) with enzalutamide (Xtandi®) 
or placebo in men with metastatic hormone-sensitive prostate 
cancer (HSPC) 
Overview 
Drug Description enzalutamide is an androgen-receptor inhibitor 
Patient Indication patients with patients metastatic HSPC, either de novo or after recurrence 
after prior local therapy.  
Incidence in 
Austria 
prostate cancer: 5,245 newly diagnosed per year (2016), 138.3/100,000 
men/year (European Standard Population, 2013) [10] 
Current standard 
treatment 
a for men with mHSPC, NICE guidelines recommend: 
- bilateral orchidectomy or continuous LHRH agonist 
therapy  
- anti-androgen monotherapy with bicalutamide; or  
- combined androgen blockade (not first-line)  
a NICE has also published an evidence summary for the off-label use 
of docetaxel (in combination with ADT) for the treatment of 
mHSPC. Docetaxel is licensed in the UK for the treatment of 
metastatic hormone-resistant prostate cancer. A draft of an update 
to the NICE guideline for prostate cancer recommends offering 
docetaxel to people who do not have significant comorbidities, 
starting treatment within 12 weeks of starting ADT, to be 
administered in six 3-weekly cycles with or without daily 
prednisolone.  
a although not currently recommended by NICE, abiraterone is 
licensed for the treatment of newly diagnosed, high risk mHSPC in 
adult men in combination with ADT plus prednisone or 
prednisolone [11]. 
Ongoing Phase III NCT02677896 (ARCHES) until 12/2023 NCT04076059 (China ARCHES) until 09/2023 [4] 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
according to product information (01/2019), enzalutamide is indicated for: 
a the treatment of adult men with high-risk non-metastatic castration-
resistant prostate cancer (CRPC) 
a the treatment of adult men with metastatic CRPC who are 
asymptomatic or mildly symptomatic after failure of ADT in whom 
chemotherapy is not yet clinically indicated 
a the treatment of adult men with metastatic CRPC whose disease 
has progressed on or after docetaxel therapy [5]. 
FDA according to label information (07/2018), enzalutamide is indicated for: 
a the treatment of patients with CRPC [6]. 
Costs  
4x28 Xtandi® 40 mg soft capsules = € 2,854.95 (ex-factory price) [7] 
 
ARCHES trial patients in the enzalutamide + ADT group received 
enzalutamide at a dose of 160 mg/day; median treatment duration in this 
group was 12.8 months. 
According to this trial regimen, 28 days of enzalutamide treatment would 
cost € 2,854.95 (12.8 months -> € 36,543.36). In addition, costs for ADT 
incur.  
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1.1.3 Published articles (PubMed): 
Journal of Clinical Oncology; available online June 6, 2019 (Armstrong et al.): “ARCHES: A 
Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in 
Men With Metastatic Hormone-Sensitive Prostate Cancer” [12] 
 
Background  
Enzalutamide, a potent androgen-receptor inhibitor, has demonstrated significant benefits in 
metastatic and nonmetastatic castration-resistant prostate cancer. We evaluated the efficacy and 
safety of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). 
 
Methods  
ARCHES (ClinicalTrials.gov identifier: NCT02677896) is a multinational, double-blind, phase III trial, 
wherein 1,150 men with mHSPC were randomly assigned 1:1 to enzalutamide (160 mg/day) or 
placebo, plus androgen deprivation therapy (ADT), stratified by disease volume and prior docetaxel 
chemotherapy. The primary end point was radiographic progression-free survival. 
 
Findings  
As of October 14, 2018, the risk of radiographic progression or death was significantly reduced with 
enzalutamide plus ADT versus placebo plus ADT (hazard ratio, 0.39; 95% CI, 0.30 to 0.50; P < .001; 
median not reached v 19.0 months). Similar significant improvements in radiographic progression-
free survival were reported in prespecified subgroups on the basis of disease volume and prior 
docetaxel therapy. Enzalutamide plus ADT significantly reduced the risk of prostate-specific antigen 
progression, initiation of new antineoplastic therapy, first symptomatic skeletal event, castration 
resistance, and reduced risk of pain progression. More men achieved an undetectable prostate-
specific antigen level and/or an objective response with enzalutamide plus ADT (P < .001). Patients 
in both treatment groups reported a high baseline level of quality of life, which was maintained over 
time. Grade 3 or greater adverse events were reported in 24.3% of patients who received 
enzalutamide plus ADT versus 25.6% of patients who received placebo plus ADT, with no 
unexpected adverse events. 
 
Interpretation  
Enzalutamide with ADT significantly reduced the risk of metastatic progression or death over time 
versus placebo plus ADT in men with mHSPC, including those with low-volume disease and/or prior 
docetaxel, with a safety analysis that seems consistent with the safety profile of enzalutamide in 
previous clinical trials in castration-resistant prostate cancer. 
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